SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 3.3%

Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) dropped 3.3% during mid-day trading on Friday . The company traded as low as $1.16 and last traded at $1.19. Approximately 573,282 shares changed hands during trading, a decline of 53% from the average daily volume of 1,209,237 shares. The stock had previously closed at $1.23.

Analyst Upgrades and Downgrades

Separately, Royal Bank of Canada upgraded SELLAS Life Sciences Group to a “moderate buy” rating in a research report on Monday, June 24th.

SELLAS Life Sciences Group Stock Performance

The business’s 50-day moving average is $1.21 and its 200 day moving average is $1.26. The company has a market cap of $76.55 million, a PE ratio of -1.08 and a beta of 2.39.

SELLAS Life Sciences Group (NASDAQ:SLS) last released its earnings results on Tuesday, August 13th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. Equities research analysts anticipate that SELLAS Life Sciences Group, Inc. will post -0.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Armistice Capital LLC bought a new position in shares of SELLAS Life Sciences Group during the fourth quarter worth $869,000. Renaissance Technologies LLC purchased a new position in shares of SELLAS Life Sciences Group during the second quarter valued at about $39,000. Anson Funds Management LP bought a new stake in shares of SELLAS Life Sciences Group in the first quarter worth about $4,881,000. Finally, Opus Capital Group LLC increased its holdings in shares of SELLAS Life Sciences Group by 48.6% in the first quarter. Opus Capital Group LLC now owns 200,600 shares of the company’s stock worth $203,000 after purchasing an additional 65,600 shares during the last quarter. Institutional investors own 17.38% of the company’s stock.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.